185 related articles for article (PubMed ID: 37215991)
1. Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1.
Yang F; Li M; Xu D; Jiang Z; Jiang H; Xiao Y; Mei C; Yang M; Chen C; Zhou B; He B; Shan H; Pang P; Li D
Int J Biol Sci; 2023; 19(8):2366-2381. PubMed ID: 37215991
[TBL] [Abstract][Full Text] [Related]
2. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
[TBL] [Abstract][Full Text] [Related]
3. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.
Hayakawa J; Depatie C; Ohmichi M; Mercola D
J Biol Chem; 2003 Jun; 278(23):20582-92. PubMed ID: 12663670
[TBL] [Abstract][Full Text] [Related]
4. C-Jun N-terminal kinase signalling pathway in response to cisplatin.
Yan D; An G; Kuo MT
J Cell Mol Med; 2016 Nov; 20(11):2013-2019. PubMed ID: 27374471
[TBL] [Abstract][Full Text] [Related]
5. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
6. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
8. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
9. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
10. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
[TBL] [Abstract][Full Text] [Related]
12. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
13. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
Potapova O; Haghighi A; Bost F; Liu C; Birrer MJ; Gjerset R; Mercola D
J Biol Chem; 1997 May; 272(22):14041-4. PubMed ID: 9162025
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
15. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.
Watanabe J; Nishiyama H; Matsui Y; Ito M; Kawanishi H; Kamoto T; Ogawa O
Oncogene; 2006 Apr; 25(17):2500-8. PubMed ID: 16518417
[TBL] [Abstract][Full Text] [Related]
16. The role of c-Jun N-terminal kinase, p38, and extracellular signal-regulated kinase in insulin-induced Thr69 and Thr71 phosphorylation of activating transcription factor 2.
Baan B; van Dam H; van der Zon GC; Maassen JA; Ouwens DM
Mol Endocrinol; 2006 Aug; 20(8):1786-95. PubMed ID: 16601071
[TBL] [Abstract][Full Text] [Related]
17. JNK suppresses tumor formation via a gene-expression program mediated by ATF2.
Gozdecka M; Lyons S; Kondo S; Taylor J; Li Y; Walczynski J; Thiel G; Breitwieser W; Jones N
Cell Rep; 2014 Nov; 9(4):1361-74. PubMed ID: 25456131
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
Xu L; Fu Y; Li Y; Han X
Cancer Chemother Pharmacol; 2017 Aug; 80(2):235-242. PubMed ID: 28597042
[TBL] [Abstract][Full Text] [Related]
19. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
20. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
Mansouri A; Ridgway LD; Korapati AL; Zhang Q; Tian L; Wang Y; Siddik ZH; Mills GB; Claret FX
J Biol Chem; 2003 May; 278(21):19245-56. PubMed ID: 12637505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
